Substituted anilide ligands for the thyroid receptor
3 Novel thyroid receptor ligands are provided having the general formula I wherein In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Washburn, William N Meng, Wei Ryono, Denis E Ellsworth, Bruce A Ericsson, Thomas Rahimi-Ghadim, Mahmoud Garg, Neeraj Malm, Johan |
| description | 3 Novel thyroid receptor ligands are provided having the general formula I wherein In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount. |
| format | Patent |
| fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07342127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07342127</sourcerecordid><originalsourceid>FETCH-uspatents_grants_073421273</originalsourceid><addsrcrecordid>eNrjZDAJLk0qLsksKS1JTVFIzMvMyUxJVcjJTE_MSylWSMsvUijJSAXiyqL8zBSFotTk1IKS_CIeBta0xJziVF4ozc2g4OYa4uyhW1pckFiSmldSHJ9elAiiDMyNTYwMjcyNiVACAC6lLgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Substituted anilide ligands for the thyroid receptor</title><source>USPTO Issued Patents</source><creator>Washburn, William N ; Meng, Wei ; Ryono, Denis E ; Ellsworth, Bruce A ; Ericsson, Thomas ; Rahimi-Ghadim, Mahmoud ; Garg, Neeraj ; Malm, Johan</creator><creatorcontrib>Washburn, William N ; Meng, Wei ; Ryono, Denis E ; Ellsworth, Bruce A ; Ericsson, Thomas ; Rahimi-Ghadim, Mahmoud ; Garg, Neeraj ; Malm, Johan ; Karo Bio AB ; Bristol-Myers Squibb Company</creatorcontrib><description>3 Novel thyroid receptor ligands are provided having the general formula I wherein In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount.</description><language>eng</language><creationdate>2008</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7342127$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,777,799,882,64018</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7342127$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Washburn, William N</creatorcontrib><creatorcontrib>Meng, Wei</creatorcontrib><creatorcontrib>Ryono, Denis E</creatorcontrib><creatorcontrib>Ellsworth, Bruce A</creatorcontrib><creatorcontrib>Ericsson, Thomas</creatorcontrib><creatorcontrib>Rahimi-Ghadim, Mahmoud</creatorcontrib><creatorcontrib>Garg, Neeraj</creatorcontrib><creatorcontrib>Malm, Johan</creatorcontrib><creatorcontrib>Karo Bio AB</creatorcontrib><creatorcontrib>Bristol-Myers Squibb Company</creatorcontrib><title>Substituted anilide ligands for the thyroid receptor</title><description>3 Novel thyroid receptor ligands are provided having the general formula I wherein In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2008</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZDAJLk0qLsksKS1JTVFIzMvMyUxJVcjJTE_MSylWSMsvUijJSAXiyqL8zBSFotTk1IKS_CIeBta0xJziVF4ozc2g4OYa4uyhW1pckFiSmldSHJ9elAiiDMyNTYwMjcyNiVACAC6lLgQ</recordid><startdate>20080311</startdate><enddate>20080311</enddate><creator>Washburn, William N</creator><creator>Meng, Wei</creator><creator>Ryono, Denis E</creator><creator>Ellsworth, Bruce A</creator><creator>Ericsson, Thomas</creator><creator>Rahimi-Ghadim, Mahmoud</creator><creator>Garg, Neeraj</creator><creator>Malm, Johan</creator><scope>EFH</scope></search><sort><creationdate>20080311</creationdate><title>Substituted anilide ligands for the thyroid receptor</title><author>Washburn, William N ; Meng, Wei ; Ryono, Denis E ; Ellsworth, Bruce A ; Ericsson, Thomas ; Rahimi-Ghadim, Mahmoud ; Garg, Neeraj ; Malm, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_073421273</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2008</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Washburn, William N</creatorcontrib><creatorcontrib>Meng, Wei</creatorcontrib><creatorcontrib>Ryono, Denis E</creatorcontrib><creatorcontrib>Ellsworth, Bruce A</creatorcontrib><creatorcontrib>Ericsson, Thomas</creatorcontrib><creatorcontrib>Rahimi-Ghadim, Mahmoud</creatorcontrib><creatorcontrib>Garg, Neeraj</creatorcontrib><creatorcontrib>Malm, Johan</creatorcontrib><creatorcontrib>Karo Bio AB</creatorcontrib><creatorcontrib>Bristol-Myers Squibb Company</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Washburn, William N</au><au>Meng, Wei</au><au>Ryono, Denis E</au><au>Ellsworth, Bruce A</au><au>Ericsson, Thomas</au><au>Rahimi-Ghadim, Mahmoud</au><au>Garg, Neeraj</au><au>Malm, Johan</au><aucorp>Karo Bio AB</aucorp><aucorp>Bristol-Myers Squibb Company</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Substituted anilide ligands for the thyroid receptor</title><date>2008-03-11</date><risdate>2008</risdate><abstract>3 Novel thyroid receptor ligands are provided having the general formula I wherein In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a Tregulated gene, wherein a compound as described above is administered in a therapeutically effective amount.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_uspatents_grants_07342127 |
| source | USPTO Issued Patents |
| title | Substituted anilide ligands for the thyroid receptor |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A55%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Washburn,%20William%20N&rft.aucorp=Karo%20Bio%20AB&rft.date=2008-03-11&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07342127%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |